A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1

被引：15

作者：

Numata, Masashi ^{[1
]}

Haginoya, Noriyasu ^{[2
]}

Shiroishi, Machiko ^{[1
]}

Hirata, Tsuyoshi ^{[2
]}

Sato-Otsubo, Aiko ^{[3
,4
]}

Yoshikawa, Kenji ^{[1
]}

Takata, Yoshimi ^{[1
]}

Nagase, Reina ^{[1
]}

Kashimoto, Yoshinori ^{[2
]}

Suzuki, Makoto ^{[2
]}

Schulte, Nina ^{[5
]}

Polier, Gernot ^{[5
]}

Kurimoto, Akiko ^{[1
]}

Tomoe, Yumiko ^{[1
]}

Toyota, Akiko ^{[1
]}

Yoneyama, Tomoko ^{[2
]}

Imai, Emi ^{[2
]}

Watanabe, Kenji ^{[1
]}

Hamada, Tomoaki ^{[1
]}

Kanada, Ryutaro ^{[1
]}

Watanabe, Jun ^{[1
]}

Kagoshima, Yoshiko ^{[1
]}

Tokumaru, Eri ^{[1
]}

Murata, Kenji ^{[1
]}

Baba, Takayuki ^{[1
]}

Shinozaki, Taeko ^{[1
]}

Ohtsuka, Masami ^{[1
]}

Goto, Koichi ^{[1
]}

Karibe, Tsuyoshi ^{[1
]}

Deguchi, Takao ^{[6
]}

Gocho, Yoshihiro ^{[6
]}

Yoshida, Masanori ^{[3
]}

Tomizawa, Daisuke ^{[6
]}

Kato, Motohiro ^{[3
,4
,6
]}

Tsutsumi, Shinji ^{[1
]}

Kitagawa, Mayumi ^{[1
]}

Abe, Yuki ^{[1
]}

机构：

[1] Daiichi Sankyo Co Ltd, Shinagawa R&D Ctr, 1-2-5 Hiromachi,Shinagawa Ku, Tokyo 1400005, Japan

[2] Daiichi Sankyo RD Novare Co Ltd, Tokyo, Japan

[3] Natl Res Inst Child Hlth & Dev, Dept Pediat Hematol & Oncol Res, Tokyo, Japan

[4] Univ Tokyo, Dept Pediat, Tokyo, Japan

[5] Daiichi Sankyo Europe GmbH, Munich, Germany

[6] Natl Ctr Child Hlth & Dev, Childrens Canc Ctr, Tokyo, Japan

来源：

CANCER CELL INTERNATIONAL | 2023年 / 23卷 / 01期

关键词：

Menin-MLL1; inhibitor; MLL1-r or NPM1c acute leukemia; Leukemia-initiating cells; STEM-CELLS; IDENTIFICATION; PROGENITOR; MODELS;

D O I：

10.1186/s12935-023-02877-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundMixed lineage leukemia 1-rearranged (MLL1-r) acute leukemia patients respond poorly to currently available treatments and there is a need to develop more effective therapies directly disrupting the Menin-MLL1 complex. Small-molecule-mediated inhibition of the protein-protein interaction between Menin and MLL1 fusion proteins is a potential therapeutic strategy for patients with MLL1-r or mutated-nucleophosmin 1 (NPM1c) acute leukemia. In this study, we preclinically evaluated the new compound DS-1594a and its salts.MethodsWe evaluated the preclinical efficacy of DS-1594a as well as DS-1594a center dot HCl (the HCl salt of DS-1594a) and DS-1594a center dot succinate (the succinic acid salt of DS-1594a, DS-1594b) in vitro and in vivo using acute myeloid leukemia (AML)/acute lymphoblastic leukemia (ALL) models.ResultsOur results showed that MLL1-r or NPM1c human leukemic cell lines were selectively and highly sensitive to DS-1594a center dot HCl, with 50% growth inhibition values < 30 nM. Compared with cytrabine, the standard chemotherapy drug as AML therapy, both DS-1594a center dot HCl and DS-1594a center dot succinate mediated the eradication of potential leukemia-initiating cells by enhancing differentiation and reducing serial colony-forming potential in MLL1-r AML cells in vitro. The results were confirmed by flow cytometry, RNA sequencing, RT-qPCR and chromatin immunoprecipitation sequencing analyses. DS-1594a center dot HCl and DS-1594a center dot succinate exhibited significant antitumor efficacy and survival benefit in MOLM-13 cell and patient-derived xenograft models of MLL1-r or NPM1c acute leukemia in vivo.ConclusionWe have generated a novel, potent, orally available small-molecule inhibitor of the Menin-MLL1 interaction, DS-1594a. Our results suggest that DS-1594a has medicinal properties distinct from those of cytarabine and that DS-1594a has the potential to be a new anticancer therapy and support oral dosing regimen for clinical studies (NCT04752163).

引用

页数：16

共 41 条

[1]

American Cancer Society, LEUK CHILDR

[2]

[Anonymous], GEN SET HESS TARG HO

[3] MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L [J].

Bernt, Kathrin M. ;

Zhu, Nan ;

Sinha, Amit U. ;

Vempati, Sridhar ;

Faber, Joerg ;

Krivtsov, Andrei V. ;

Feng, Zhaohui ;

Punt, Natalie ;

Daigle, Amanda ;

Bullinger, Lars ;

Pollock, Roy M. ;

Richon, Victoria M. ;

Kung, Andrew L. ;

Armstrong, Scott A. .

CANCER CELL, 2011, 20 (01) :66-78

[4] Leukemia Stem Cells and Human Acute Lymphoblastic Leukemia [J].

Bernt, Kathrin M. ;

Armstrong, Scott A. .

SEMINARS IN HEMATOLOGY, 2009, 46 (01) :33-38

[5] Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+Stem- and Progenitor cells in Acute Lymphoblastic Leukemia [J].

Blatt, Katharina ;

Menzl, Ingeborg ;

Eisenwort, Gregor ;

Cerny-Reiterer, Sabine ;

Herrmann, Harald ;

Herndlhofer, Susanne ;

Stefanzl, Gabriele ;

Sadovnik, Irina ;

Berger, Daniela ;

Keller, Alexandra ;

Hauswirth, Alexander ;

Hoermann, Gregor ;

Willmann, Michael ;

Rulicke, Thomas ;

Sill, Heinz ;

Sperr, Wolfgang R. ;

Mannhalter, Christine ;

Melo, Junia V. ;

Jager, Ulrich ;

Sexl, Veronika ;

Valent, Peter .

NEOPLASIA, 2018, 20 (06) :632-642

[6] Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo [J].

Borkin, Dmitry ;

He, Shihan ;

Miao, Hongzhi ;

Kempinska, Katarzyna ;

Pollock, Jonathan ;

Chase, Jennifer ;

Purohit, Trupta ;

Malik, Bhavna ;

Zhao, Ting ;

Wang, Jingya ;

Wen, Bo ;

Zong, Hongliang ;

Jones, Morgan ;

Danet-Desnoyers, Gwenn ;

Guzman, Monica L. ;

Talpaz, Moshe ;

Bixby, Dale L. ;

Sun, Duxin ;

Hess, Jay L. ;

Muntean, Andrew G. ;

Maillard, Ivan ;

Cierpicki, Tomasz ;

Grembecka, Jolanta .

CANCER CELL, 2015, 27 (04) :589-602

[7] MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)-Current Treatment Options. Is There a Role for CAR-T Cell Therapy? [J].

Britten, Oliver ;

Ragusa, Denise ;

Tosi, Sabrina ;

Kamel, Yasser Mostafa .

CELLS, 2019, 8 (11)

[8] Interaction of MLL amino terminal sequences with menin is required for transformation [J].

Caslini, Corrado ;

Yang, Zhaohai ;

El-Osta, Mohamad ;

Milne, Thomas A. ;

Slany, Robeft K. ;

Hess, Jay L. .

CANCER RESEARCH, 2007, 67 (15) :7275-7283

[9] MLL rearrangements in haematological malignancies: Lessons from clinical and biological studies [J].

DiMartino, JF ;

Cleary, ML .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (03) :614-626

[10] Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. [J].

Falini, B ;

Mecucci, C ;

Tiacci, E ;

Alcalay, M ;

Rosati, R ;

Pasqualucci, L ;

La Starza, R ;

Diverio, D ;

Colombo, E ;

Santucci, A ;

Bigerna, B ;

Pacini, R ;

Pucciarini, A ;

Liso, A ;

Vignetti, M ;

Fazi, P ;

Meani, N ;

Pettirossi, V ;

Saglio, G ;

Mandelli, F ;

Lo-Coco, F ;

Pelicci, P ;

Martelli, MF .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) :254-266

← 1 2 3 4 5 →